'Tactical approval delays' steer Eisai beyond Europe
This article was originally published in Scrip
Much has been made of the opportunities for rapid growth in emerging markets including those of central and eastern Europe and the Middle East. Companies are being tempted there not just by the carrot of increased health spending in those markets, but by the stick of the increasingly hostile environment they are experiencing in established European markets. Eisai is a case in point, with its EU chief Gary Hendler recently seeing his remit expanded to a broader focus on the EMEA (Europe, Middle East and Africa).
You may also be interested in...
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.